Angioimmunoblastic T‐cell lymphoma and Kaposi sarcoma: A fortuitous collision?
Histopathology · 2024
DOI: 10.1111/his.15083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Elsa Poullot und 14 weiteren Autor:innen. Beteiligte Einrichtung: Département de Pathologie, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France. Hauptthemen laut MEDLINE: Sarcoma, Kaposi, Epstein-Barr Virus Infections, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Follicular helper T‐cell (TFH) lymphoma of the angioimmunoblastic‐type (AITL), one of the most prevalent T‐cell lymphomas, typically encompasses proliferation of high endothelial venules and Epstein–Barr virus‐positive immunoblasts, but neither infection with HHV8 nor association with Kaposi's sarcoma (KS) have been described. The aims of this study are to characterise the association between AITL and HHV8 infection or KS. Methods and results Three male patients aged 49–76 years, HIV‐negative, with concurrent nodal involvement by AITL and KS, were identified from our files and carefully studied. Two patients originated from countries where endemic KS occurs, including one with cutaneous KS. The lymphomas featured abundant vessels, expanded follicular dendritic cells and neoplastic TFH cells [PD1+ (three of three), ICOS+ (three of three), CXCL13+ (three of three), CD10 + (two of three), BCL6 (two of three)] but lacked EBV+ immunoblasts. The foci of KS consisted of subcapsular proliferations of ERG+, CD31 + and/or CD34 + , HHV8+ spindle cells. High‐throughput sequencing showed AITL‐associated mutations in TET2 (three of three), RHOA ( G17V ) (three of three) and IDH2 ( R172 ) (two of three), which were absent in the microdissected KS component in two cases. Relapses in two patients consisted of AITL, without evidence of KS. No evidence of HHV8 infection was found in a control group of 23 AITL cases.
Conclusion
Concurrent nodal involvement by AITL and KS is rare and identification of both neoplastic components may pose diagnostic challenges. The question of whether the association between AITL and KS may be fortuitous or could reflect the underlying immune dysfunction in AITL remains open.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Département de Pathologie, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France.
- Université Paris Est Créteil, Créteil, France.
- INSERMU955, Institut Mondor de Recherche Biomédicale, Créteil, France.
- Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland.
- Unité Hémopathies Lymphoïdes, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France.
- Clinique Bois-Cerf, Lausanne, Switzerland.
ORCID-Profile: Laurence de Leval, Philippe Gaulard
Zitieren
APA
Poullot, E., Milowich, D., Lemonnier, F., Bisig, B., Robe, C., Pelletier, L., Letourneau, A., Dupuy, A., Sako, N., Ketterer, N., Carde, P., Dartigues, P., Delfau-Larue, M. H., de Leval, L., & Gaulard, P. (2024). Angioimmunoblastic T‐cell lymphoma and Kaposi sarcoma: A fortuitous collision?. Histopathology. https://doi.org/10.1111/his.15083
Vancouver
Poullot E, Milowich D, Lemonnier F, Bisig B, Robe C, Pelletier L, et al. Angioimmunoblastic T‐cell lymphoma and Kaposi sarcoma: A fortuitous collision?. Histopathology. 2024. doi:10.1111/his.15083
BibTeX
@article{Poullot2024,
author = {Poullot, Elsa and Milowich, Dina and Lemonnier, François and Bisig, Bettina and Robe, Cyrielle and Pelletier, Laura and Letourneau, Audrey and Dupuy, Aurélie and Sako, Nouhoum and Ketterer, Nicolas and Carde, Patrice and Dartigues, Peggy and Delfau-Larue, Marie-Hélène and de Leval, Laurence and Gaulard, Philippe},
title = {Angioimmunoblastic T‐cell lymphoma and Kaposi sarcoma: A fortuitous collision?},
journal = {Histopathology},
year = {2024},
doi = {10.1111/his.15083}
}
EUVIMED